ARCHIVES

Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles With SEC Over Shorting Dendreon Stock

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Velcade Plus Dexamethasone Provides 20% Response In First-Line Treatment

December 29, 2006

EntreMed Issued U.S. Patent For Active Parts Of Endostatin.

March 2, 2001

John Niederhuber named NCI chief operating officer; the surgeon was asked to leave two previous positions.

October 7, 2005

Science Policy: Stem Cell Research Guidelines Formalize NIH Funding Polices

December 3, 1999

Pertuzumab Delays Progression In HER2-Positive Breast Cancer

August 26, 2011

LabCorp Marketing Of Ovarian Cancer Test Unlawful, FDA Says In Warning Letter.

October 17, 2008